Effect of hesperdin isolated from orange peels on cisplatin-induced nephrotoxicity

International Journal of Pharmacognosy and Phytochemical Research

Volumn 4, Issue 2, 2012, Pages 49-53

  Adikay, Sreedevi ^a   Spandana, U ^a   Bharathi, K ^a  

^a INSTITUTE OF PHARMACEUTICAL TECHNOLOGY   (India)

Author keywords

Cisplatin; Hesperidin; Nephrotoxicity

Indexed keywords

CISPLATIN; CREATININE; FLAVANONE; HESPERDIN; NITROGEN; UNCLASSIFIED DRUG; UREA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DOSE RESPONSE; DRUG DOSE COMPARISON; LIPID PEROXIDATION; MALE; NEPHROTOXICITY; NONHUMAN; ORANGE (FRUIT); PROTEINURIA; RAT; RENAL PROTECTION; STOMACH INTUBATION; UREA NITROGEN BLOOD LEVEL;

EID: 84863827044     PISSN: None     EISSN: 09754873     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Wittshaw E, Cisplatin NDA amendment 1977; 4.2: 00163
2. John D. Hainsworth, and F. Anthony Greco Treatment of Patients with Cancer of an Unknown Primary Site 1993; New Eng. J. Med.; 329(4): 257-63.
3. Zanetta G, Fei F, Parma G, Balestrino M, Lissoni A, Gabriele A and Mangioni C. Paclitaxel, ifosfamide and cisplatin (TIP) chemotherapy for recurrent or persistent squamous-cell cervical cancer 1999; Cancer; 10(10): 1171-74.
4. Merrin C; Systemic chemotherapy in inoperable (or) metastalic bladder cancer; J. Urol. 1978; 119: 522.
5. Burch PA; Phase II Trial of Combination Paclitaxel and Cisplatin in Advanced Urothelial Carcinoma (UC) (Meeting abstract); ASCO Annual Meeting 1999; Ab.No.1266.
6. Amer MH, Izbicki R and Al-Sarraf M; Termozolamide and whole brain irradiation in melanoma metastatic to the brain: a phase II trial of the cytokinine Melanoma and central nervous system metastates.; Proc. Am. Soc. Clin. Oncol; 1978;19: 312.
7. Badary, O.A., Nagi, M.N., Al-Sawaf, H.A., Al-Harbi, M., Al-Bekairi, A.M., Effect of L-histidinol on cisplatinnephrotoxicity in the rat. Nephron. 1997a;77 (4), 435-439.
8. Espana P, Smith F, Ahrams J. Haidak D, Veno W, Wooley P and Schein P Phase-II Study of Cis-diammine-dichloro platinum (cisplatinum), bleomycin and methorexate for advanced squamous cell carcinoma of head and neck, Can. Chemother. Pharmacol. 1984;12(2): 98-100.
9. Marcial VA, Pajak TF, Mohiuddin M, Cooper JS, Al Sarraf M, Mowry PA Curran W, Crissman J, Rodriguez MVelez-Garcia E. Concomitant cisplatin chemotherapy and radiotherapy in advanced mucosal squamous cell carcinoma of the head and neck. Long-term results of the Radiation Therapy Oncology Group study; Cancer; 66(9): 1861-68.
10. Bunn PA Jr. 1989; The expanding role of cisplatin in the treatment of non-small-cell lung cancer; Semin Oncol. 1990;16(4 Suppl 6): 10-21.
11. Crino L, Clerici M, Figoli F, Carlini P, Ceci G, Cortesi E, Carpi A, Santini A, Dicostanzo F, Boni C Chemotherapy of advanced non-small-cell lung cancer: a comparison of three active regimens; A randomized trial of the Italian Oncology Group for Clinical Research (G.O.I.R.C.); Ann Oncol. 1995; 6(4): 347-53.
12. Karen Kelly, John Crowley, Paul A, Bunn Jr., Cary A, Presant, Patrak, Grevstad, Carol M., Moin Pour, Scott D. Ramsay, Antoinette J, Wozniak, Geoffery R, Weiss, Dennis F Noore, Valerie K. Israel, Robert B. Livingston and David R. Candara Randamized Phase III trial of Paclitaxel plus Carboplatin versus Vinorelbine plus cisplatin in the treatment of patients with advanced non-small-all lung cancer; A South West Oncology Group Trial; J. Clin. Oncol. 2001; 19 (13): 3210-18.
13. Cork G, Goksel T, Sover S, Atil H, Guzelant A, Aysan T Comparing cisplatin plus etoposide with combination of mitomycin, ifosfamide and cisplatin in advanced non-small cell lung cancer patients; Tuberk Toraks. 2006;54(2): 161-67
14. Di Re, F., Bohm, S., Oriana, S., Spatti, G.B., Zunino, F., Efficacy and safety of high-dose cisplatin and cyclophosphamidewith glutathione protection in the treatment of bulky advanced epithelial ovarian cancer. Cancer Chemotherapy andPharmacology 1990;25, 355-360.
15. Deconti, R.C., Toftness, B.R., lange, R.C., creasey, W.A. Clinical and pharmacological studies with cis-diamminedichloroplatinum (II). Cancer Research 1973;33(6), 1310-1315.
16. Ishikawa, M., Takayanagi, Y., Sasaki, K. Enhancement of cisplatin toxicity by buthionine sulfoximine, a glutathione-depleting agent, in mice. Research Communications of Chemical Pathology and Pharmacology 1990;67 (1), 131-141.
17. Zhang, J. G, and Lindup, W. E. Role of mitochondria in cisplatininduced oxidative damage exhibited by rat renal cortical slices. Biochem.Pharmacol. 1993;45, 2215-2222.
18. Meyer KB, Madias, NE and Miner Toxicities of Cisplatin; Electrolyte Metab. 1994;20: 201-13.
19. Bompart G Cisplatin-induced changes in cytochrome P-450, lipid peroxidation and drug-metabolizing enzyme activities in rat kidney cortex.; Toxicol Lett. Aug 1989;48(2): 193-199.
20. Yoshida M, Sakai T, Hosokawa N, Marui N, Matsumoto K, Fujioka A, Nishino H, and Aoike A. The effect of quercetin on cell cycle progression and growth of human gastric cancer cells. FEBS Lett 1990;260: 10-13.
21. Lieberthal W, Triaca V, and Levine J. Mechanisms of death induced bycisplatin in proximal tubular epithelial cells: apoptosis vs. necrosis. J Am Cell Physiol 1996;270:F700-F708.
22. Badary, O.A., Nagi, M.N., Al-Shabanah, O.A., Al-Sawaf, H.A., Al-Sohaibani, M.O., Al-Bekairi, A.M.,. Thymoquinone ameliorates the nephrotoxicity induced by cisplatin in rodents and potentiates its antitumor activity. Canadian Journal of Physiology and Pharmacology 1997b; 75 (12), 1356-1361.
23. Somani, S.M., Husain, K., Whitworth, C., Trammell, G.L., Malafa, M., Rybak, L.P. Dose-dependent protection by lipoic acid against cisplatin-induced nephrotoxicity in rats: Antioxidant defense system. Pharmacology and Toxicology 2000;86 (5),234-241
24. Shimeda Y, Hirotani Y., Akimoto Y, Shindov K, Ijiri Y, Nishihori T and Tanaka K 2005; Protective effects of capsacin against cisplatin-induced nephrotoxicity in rats; Biol. Pharm. Bull; 28 (9): 1635-38.
25. Greggi ALM, Darim JD and Bianchi MD Protective effects of Vitamin C against cisplatin-induced nephrotoxicity and lipid peroxidation in adult rats; A dose dependent study, Pharmacol. Res. 2000; 4(1): 405-07.
26. Antunes LM, Darin JD, and Bianchi Nole L. Effects of the antioxidants curcumin or selenium on cisplatin-induced nephrotoxicity and lipid peroxidation in rats 2001; Pharmcol. Res; 43(2): 145-50.
27. Middleton Jr., E., Kandaswami, C., Theoharides, T.C. The effects of plant flavonoids on mammalian cells: implicationsfor inflammation, heart disease, and cancer. Pharmacological Reviews 2000;52 (4), 673-751.
28. Devi Priya S. and Shyamala Devi CS. Protective effect of quercetin in cisplatin-induced cell injury in the rat kidney; Ind. J. Pharmacol.; 1999; 31: 422-426.
29. Osama A Badary, Sahar Abdel.K.Soud Wafaa A, Ahmed, Gehan, H.Owieda. Palestine, A.G., Austin, H.A., Balow, J.E., Antonovych, T.T., Sabnis, S.G., Preuss, H.G., & Nussenblatt, R.B. Renal histo-Pathologic alterations in patients treated with Engl. J.Cyclosporine for crveitis. New Med. 1986;314; 1293-1298.
30. Ohkawa, H., Ohishi, N., and Yagi, K., Assay for lipid peroxides inanimals and tissues by thiobarbituric acid reaction. Anal. Biochem1979;95,351-358.
31. Prestayko AW, Crooke ST, Carter SK 1980; Cisplatin: Current status and New Developments; Eds. Academic, New York.
32. Bull JMC, Strebel FR, Sunderland BA, Bulger FE, Edwards M, Siddik ZH and Newman RA O-β-hydroxyethyl-rutoside mediated Protection of renal injury associated with cis-diamino-dichloroplatinum/hyperthermia treatment.; Cancer Res; 1988;48: 2239-44.
33. Baldew GS, Vanden Hamer CJA, Los G, Vermuelen NPE, de Goeij JJM, and Mcvie JG Selenium induced protection against cis-diaminodichloroplatinum nephrotoxicity in mice and rats.; Cancer Res. 1989; 49: 3020-23.
34. Inselmann G, Blohmer A, Kottny W, Nellessen U, Hanel H and Heidemann HT. Modification of cisplatin-induced renal p-aminohippurate uptake alteration and lipid peroxidation by thiols, Ginkgo biloba extract, deferoxamine and torbafylline. Nephron; 1995;70(4):425-29.
35. Sugihara K, Nakano S and Gemba M. Effect of cisplatin on in vitro production of lipid peroxides in rat kidney cortex.; Jpn. J. Pharmacol.; 1987;44(1): 71-6
36. Li Q, Bowmer CJ, and Yates MS, The protective effect of glycine in cisplatin nephrotoxicity: inhibition with NG-nitro-L-arginine methyl ester; J. Pharm. Pharmacol.; 1994;46(5): 346-51.
37. Srivastava, V.; Vasil, V. and Vasil, I.K. Molecular characterization of the fate of transgenes in transformed wheat (Triticum aestivum L.). Theoretical and Applied Genetics 1996;92:1031-1037.
38. 2- production in cisplatin-induced nephrotoxicity.; Biochem. Biophys. Res. Commun. 1998; 242: 310-12.
39. Schilsky Rl and Anderson T Hypomagnesemia and renal magnesium wasting in patients receiving cisplatin; Ann. Int. Med.; 1979;90(6): 929-31.
40. Dubach UC, LE Hir M and Gandhi R; Use of urinary enzymes as markers of nephrotoxicity; Toxicol. Lett. 1989;46: 193-96.
41. Dobyan, D.C., Bull, J.M., Strebel, F.R., Sunderland, B.A., Bulger, R.E. Protective effect of 0-(beta-hydroxyethyl)-rutoside on cis-platinum-induced acute renal failure in the rat. Laboratory Investigation 1986;55, 557-563
42. Mayer KB and Madias NE Cisplatin toxicities; Electrolyte Metab. 1994;20: 201-13.
43. Sreedevi Adikay, Bharathi Koganti, Prasad, KVSRG. "Effect of decoction of root bark of Berberis aristata on Cisplatin- induced Nephrotoxicity in rats". International Journal of Pharmacy and Pharmaceutical Sciences, 2010, 2(3), 51-56.
44. Cook, N.C., Samman, S. Flavonoids-chemistry, metabolism, cardioprotectivew effects and dietary sources. Journal ofNutrition and Biochemistry 1996;7, 66-76.
45. Benavente-Gracia, O., Castillo, J., Marin, F.R., Ortuno, A., Del Rio, J.A. Uses and properties of citrus flavonoids. Journal of agricultural and food chemistry 1997;45, 4505-4515
46. Heidemann, Gerkens J, Jackson EK, and Branch RA. Attenuation of Cisplatin-induced nephrotoxicity in the rat by high salt diet furosemide and acetazolamide; Naunyn Schmiedeberg's Arch. Pharmocol. 1989;329: 201-05.
47. Rybak, L. P., Ravi, R., and Somani, S. M. Mechanism of protectionby diethyldithiocarbamate against cisplatin ototoxicity: Antioxidant system. Fundam. Appl. Toxicol.1995; 26, 293-300.
48. Dobyan Dennis C, Joseph Levi, Charlotte Jacobs, Jon Kosek and Michael W. Winner. Mechanism of ciplatinum nephrotoxicity: II Morphyological observations; J. Pharmcol. Exp. Ther.; 1980;213 (3): 551-56.